Global Endometriosis Market 2012-2016


◆タイトル:Global Endometriosis Market 2012-2016
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Five UserUSD2,300 ⇒換算¥250,700見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



TechNavio’s analysts forecast the Global Endometriosis market to grow at a CAGR of 5.86 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased number of incidence rates of endometriosis. The market has also been witnessing an increased number of awareness programs. However, poor safety and efficacy of existing drugs could pose a challenge to the growth of this market.

TechNavio’s report, the Global Endometriosis Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Endometriosis market in the Americas, EMEA, and the APAC regions, its market landscape, and growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space include AbbVie Inc., AstraZeneca Plc., Bayer Inc., and Pfizer Inc.

The other vendors mentioned in the report are AEterna Zentaris Inc., KV Pharmaceuticals Company, Neurocrine Biosciences Inc., and Repros Therapeutics Inc.

Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.


1. Executive Summary
2. List of Abbreviations
3. Introduction
4. Market Research Methodology
4.1. Market Research Process
4.2. Research Design
4.3. Research Methodology
5. Scope of the Report
5.1. Market Overview
5.2. Product Offerings
5.3. Product Profiles
6. Market Landscape
6.1. Global Endometriosis market 2012-2016
6.1.1. Market Size and Forecast
7. Five Force Analysis
8. Geographical Segmentation
9. Rate of Incidence and Prevalence
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
17.1. AbbVie Inc.
17.1.1. Business Overview
17.1.2. Key Information
17.1.3. SWOT Analysis
17.2. Pfizer Inc.
17.2.1. Business Overview
17.2.2. Key Information
17.2.3. SWOT Analysis
17.3. AstraZeneca PLC.
17.3.1. Business Overview
17.3.2. Key Information
17.3.3. SWOT Analysis
17.4. Bayer Inc.
17.4.1. Business Overview
17.4.2. Key Information
17.4.3. SWOT Analysis

18. Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Global Endometriosis Market 2012-2016 (US$ billion)
Exhibit 3: Therapies Used in the Treatment of Endometriosis
Exhibit 4: Therapies Used in the Treatment of Endometriosis (in percentage)
Exhibit 5: Global Endometriosis Market by Geographical Segmentation 2012


AbbVie Inc., AstraZeneca plc, Bayer Inc., Pfizer Inc., AEterna Zentaris Inc., KV Pharmaceuticals Company, Neurocrine Biosciences Inc., and Repros Therapeutics Inc.



★調査レポート[世界の子宮内膜症(Endometriosis)市場動向(2012-2016)] (Global Endometriosis Market 2012-2016 / IRTNTR2183)販売に関する免責事項
[世界の子宮内膜症(Endometriosis)市場動向(2012-2016)] (Global Endometriosis Market 2012-2016 / IRTNTR2183)についてEメールでお問い合わせ